{"title":"原发性可手术乳腺癌TP53体细胞突变与预后因素:对应关系。","authors":"Pathum Sookaromdee, Viroj Wiwanitkit","doi":"10.4048/jbc.2022.25.e51","DOIUrl":null,"url":null,"abstract":"de Groot S, Baak-Pablo R, Kranenbarg EM, Seynaeve CM, van de Velde CJ, et al. The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. Sci Rep 2021;11:3249. PUBMED | CROSSREF","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"522"},"PeriodicalIF":2.2000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/c9/jbc-25-522.PMC9807318.pdf","citationCount":"1","resultStr":"{\"title\":\"Somatic Mutations of <i>TP53</i> and Prognostic Factors for Primary Operable Breast Cancer: Correspondence.\",\"authors\":\"Pathum Sookaromdee, Viroj Wiwanitkit\",\"doi\":\"10.4048/jbc.2022.25.e51\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"de Groot S, Baak-Pablo R, Kranenbarg EM, Seynaeve CM, van de Velde CJ, et al. The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. Sci Rep 2021;11:3249. PUBMED | CROSSREF\",\"PeriodicalId\":15206,\"journal\":{\"name\":\"Journal of Breast Cancer\",\"volume\":\"25 6\",\"pages\":\"522\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/c9/jbc-25-522.PMC9807318.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Breast Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4048/jbc.2022.25.e51\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4048/jbc.2022.25.e51","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Somatic Mutations of TP53 and Prognostic Factors for Primary Operable Breast Cancer: Correspondence.
de Groot S, Baak-Pablo R, Kranenbarg EM, Seynaeve CM, van de Velde CJ, et al. The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. Sci Rep 2021;11:3249. PUBMED | CROSSREF
期刊介绍：
The Journal of Breast Cancer (abbreviated as ''J Breast Cancer'') is the official journal of the Korean Breast Cancer Society, which is issued quarterly in the last day of March, June, September, and December each year since 1998. All the contents of the Journal is available online at the official journal website (http://ejbc.kr) under open access policy. The journal aims to provide a forum for the academic communication between medical doctors, basic science researchers, and health care professionals to be interested in breast cancer. To get this aim, we publish original investigations, review articles, brief communications including case reports, editorial opinions on the topics of importance to breast cancer, and welcome new research findings and epidemiological studies, especially when they contain a regional data to grab the international reader''s interest. Although the journal is mainly dealing with the issues of breast cancer, rare cases among benign breast diseases or evidence-based scientifically written articles providing useful information for clinical practice can be published as well.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
